Please note our distinction between *precision health (PH)* and *precision medicine (PM)*. Be sure that your proposal falls within the scope of this definition PH and **NOT PM** in order to be considered for this seed/dream team funding opportunity. Namely, therapies, drug screening, therapeutic efficacy, and existing disease states and/or conditions are outside the scope of PH. Think about approaches to keep people as healthy as possible, rather than interventions and treatments of already existing diseases.

The following examples should aid in clarifying the differences:

**PH:** Using –omics/biomarkers for prediction of future disease occurrence in healthy individuals or populations.

**PM:** Using –omics/biomarkers for prediction, development, or validation of treatments/therapies and drug sensitives.

**PH:** Wearable/nanotechnology for early diagnostics of disease or to better understand the transition from health to disease.

**PM:** Wearable/nanotechnology to predict recovery from condition/disease or monitor progression of prevalent condition/disease.

**PH:** Strategies for early disease detection

**PM:** Strategies for monitoring for disease recurrence in someone who has already previously been treated for the disease

**PH:** Predicting risk of a given disease based on multiple factors

**PM:** Predicting response to therapy or monitoring response to therapy

There of course will be numerous possibilities, but overall proposals should involve an approach that is intended to be applied to a healthy individual or population(s) (prior to the occurrence of disease and of a non-therapeutic nature). Remember to contact Dr. Ryan Spitler if you are not sure if your research might fit into the PHIND Center goals.